In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies, with a price target of $54.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Liquidia Technologies’ promising outlook. The company recently showcased new data from its lead product, Yutrepia, at the PHPN Symposium, emphasizing its strong safety and efficacy profile. This data reinforces Yutrepia’s potential as a key treatment for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, particularly in the relatively untapped market segment of PH-ILD.
Additionally, there are growth opportunities for Yutrepia in the PAH market, including the potential to convert patients from other treatments like Tyvaso and oral prostacyclins. Liquidia is strategically positioned to capitalize on these opportunities, as it targets patient segments that have not been fully addressed by competitors. This strategic focus, combined with the strong clinical data, supports the Buy rating as the company is poised for significant market expansion.
According to TipRanks, Jubinville, PhD is a 4-star analyst with an average return of 15.3% and a 50.00% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Crinetics Pharmaceuticals.